218 related articles for article (PubMed ID: 19524946)
1. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
Gardner TA; Logan T
J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
[No Abstract] [Full Text] [Related]
2. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy.
Kishida T; Yao M; Uemura H; Ohlmann C; Tomita Y; Bukowski RM; Naito S
Int J Urol; 2010 Mar; 17(3):198-205. PubMed ID: 20409215
[No Abstract] [Full Text] [Related]
3. [Interferon-based cytokine therapy for advanced renal cell carcinoma].
Takayama T; Kai F; Sugiyama T; Furuse H; Mugiya S; Ozono S
Hinyokika Kiyo; 2005 Aug; 51(8):499-502. PubMed ID: 16164263
[TBL] [Abstract][Full Text] [Related]
4. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
5. The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness.
Panelli MC; Wang E; Marincola FM
Clin Cancer Res; 2005 May; 11(10):3601-3. PubMed ID: 15897553
[No Abstract] [Full Text] [Related]
6. The multidrug resistance gene in renal cell carcinoma.
Klein EA
Semin Urol; 1989 Nov; 7(4):207-14. PubMed ID: 2575783
[No Abstract] [Full Text] [Related]
7. [Two cases of renal cell carcinoma with ascites after interleukin-2 therapy].
Kobori G; Maegawa M; Ushida H; Maekawa S; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2002 Jul; 48(7):455-7. PubMed ID: 12229188
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2-induced seborrhoeic dermatitis-like eruption.
Yamamoto T; Tsuboi R
J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):244-5. PubMed ID: 18211425
[No Abstract] [Full Text] [Related]
9. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
McDermott DF; Atkins MB
Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
[TBL] [Abstract][Full Text] [Related]
10. Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer.
Srinivasan R; Linehan WM
J Clin Oncol; 2005 Jan; 23(3):410-2. PubMed ID: 15572728
[No Abstract] [Full Text] [Related]
11. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
Dutcher JP
Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
[No Abstract] [Full Text] [Related]
12. Improving the therapeutic index of IL-2.
McDermott DF
Clin Adv Hematol Oncol; 2010 Dec; 8(12):862-4. PubMed ID: 21326162
[No Abstract] [Full Text] [Related]
13. Renal-cell carcinoma.
Vincenzi B; Santini D; Tonini G
N Engl J Med; 2006 Mar; 354(10):1095-6; author reply 1095-6. PubMed ID: 16528812
[No Abstract] [Full Text] [Related]
14. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
15. Highlights from the Eigth International Kidney Cancer Symposium.
Hutson T
Clin Adv Hematol Oncol; 2009 Dec; 7(12):796-8. PubMed ID: 20332749
[No Abstract] [Full Text] [Related]
16. Establishing the role of cytokine therapy in advanced renal cell carcinoma.
Gore ME; De Mulder P
BJU Int; 2008 May; 101(9):1063-70. PubMed ID: 18279450
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of a patient on adrenal steroid replacement therapy with high-dose bolus interleukin-2 for metastatic renal cell carcinoma.
Deshpande H; Dutcher JP; Novik Y; Oleksowicz L
Cancer J Sci Am; 1999; 5(1):52-3. PubMed ID: 10188062
[No Abstract] [Full Text] [Related]
18. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
Vieweg J
Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
[No Abstract] [Full Text] [Related]
19. [Prognostic factors in kidney cancer].
Patard JJ
Prog Urol; 2007 Feb; 17(1 Suppl 1):139-43. PubMed ID: 17571637
[No Abstract] [Full Text] [Related]
20. [Molecular characterization of metastatic renal cell carcinomas. Differentiation of prognosis and therapy].
Junker K; Sanjmyatav J; Heinze C; Walter M; Heinzelmann J; Wunderlich H; Schubert J; Steiner T
Urologe A; 2008 Sep; 47(9):1187-9. PubMed ID: 18688592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
